CD4 News and Research

RSS

SARS-CoV-2 variants partially escape humoral immunity, but not T cells responses, study finds

Researchers at the Department of Viroscience, Erasmus MC, National Institute for Public Health and the Environment, Amsterdam UMC, and the Weill Medical College of Cornell University studied humoral and cellular immune responses to the wild type SARS-CoV-2, the B.1.1.7 variant (U.K. variant) and the B.1.351 variant (South African variant) in health care workers vaccinated with the BNT162b2 (Pfizer-BioNTech) mRNA vaccine.

31 May 2021

A novel multi-epitope COVID-19 vaccine developed using reverse vaccinology

A new study has been published in the Journal of Biomolecular Structure and Dynamics which focuses on the evaluation of E, M, N, ORF10, ORF8, ORF3a, and M proteins using bioinformatics tools to develop a multi-epitope COVID-19 vaccine. The researchers utilized in-silico methods to incite humoral and cellular immune responses.

31 May 2021

Intensity and duration of SARS-CoV-2 immunity may depend on ABO blood group

A team of scientists from Canada and Spain recently evaluated the durability of antigen-specific immune responses in COVID-19 recovered individuals. They have also identified potential host factors associated with robust and long-lasting anti-SARS-CoV-2 immunity.

26 May 2021

Tissue-resident memory T cells found in lungs of people who had COVID-19 10 months ago

In recent research by Judith Grau-Expósito et al., scientists identify circulating virus-specific T cell responses during acute SARS-CoV-2 infection with functional, migratory, and apoptotic patterns modulated by viral proteins and associated with clinical outcome.

26 May 2021

An exploratory study of T-cell and antibody responses after COVID-19 mRNA vaccination

Recent COVID-19 investigations have found that up to half of immunocompromised individuals struggle to produce antibodies after receiving their severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccinations.

26 May 2021

Immunologists decode T cell responses that occur during COVID-19 infection

An international team of researchers from the Institute for Research in Biomedicine, affiliated to the Università della Svizzera italiana, has deciphered, at single cell resolution, the T cell responses occurring during COVID-19 infection.

26 May 2021

Human T cells can target more than 1,400 sites on SARS-CoV-2 virus

In a new paper, scientists from La Jolla Institute for Immunology (LJI) bring together research findings from COVID-19 researchers around the world.

25 May 2021

Next-generation SARS-CoV-2 subunit vaccine candidate elicits powerful immunity in preclinical trials

New research – by scientists at the University of Chicago, Johns Hopkins School of Medicine and the University of Iowa in the USA – describes a novel COVID-19 vaccine candidate that has achieved impressive immunologic results in mouse studies.

25 May 2021

Facets of SARS-CoV-2 infection and animal models

A new study in the journal Frontiers in Cell and Developmental Biology discusses the ribonucleic acid (RNA) genome of the virus, and the mechanisms by which it establishes infection within the host cell. The researchers also summarize the development of animal models of COVID-19, which will both help understand the clinical features of the illness, and indicate new approaches for the treatment of the infection.

21 May 2021

Are COVID-19-related complications in children explained by abnormal immune responses?

A common theme in reports on COVID-19 around the world has been the large number of children who have not been infected or shown signs of disease. However, though the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes less acute infection in this age group, it is associated with a severe immune-mediated multisystemic illness called multisystem inflammatory syndrome in children (MIS-C).

20 May 2021

COVID-19 mRNA vaccines safe and effective for pregnant and breastfeeding women

The current coronavirus disease 2019 (COVID-19) pandemic has brought untold devastation in its wake, with its rapid and asymptomatic spread to hundreds of millions of people the world over. Vaccines have been hailed as the way out of this situation, and a dozen or so are being rolled out in many different countries.

18 May 2021

Moderna and Pfizer-BioNTech vaccines induce robust T cell response against SARS-CoV-2 variants

Researchers in the United States have conducted a study showing the efficacy of the Moderna and Pfizer-BioNTech vaccines at eliciting a robust T cell response against variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

16 May 2021

Unique pre-clinical model enables study of HIV infection and testing of new therapies

A team led by researchers at Weill Cornell Medicine and Children's National Hospital has developed a unique pre-clinical model that enables the study of long-term HIV infection, and the testing of new therapies aimed at curing the disease.

14 May 2021

Pfizer-BioNTech COVID-19 vaccine effective in patients with myeloproliferative neoplasms

Researchers in the UK have provided evidence that Pfizer-BioNTech’s coronavirus disease 2019 (COVID-19) vaccine induces effective immune responses in patients with myeloproliferative neoplasms.

13 May 2021

T cell populations in nasal mucosa expand after COVID-19 mRNA vaccination

A new study released as a bioRxiv* preprint tried to establish how tissues such as the upper respiratory tract (URT) – which harbor the virus and often act as the point of entry – are difficult to access for routine testing, but are responsive to vaccination.

11 May 2021

Research suggests Pfizer-BioNTech COVID-19 vaccine reprograms innate immune responses

Researchers in The Netherlands have warned that Pfizer-BioNTech’s coronavirus disease 2019 (COVID-19) vaccine induces complex reprogramming of innate immune responses that should be considered in the development and use of mRNA-based vaccines.

10 May 2021

Combo COVID-flu vaccine protects against current and emerging variants in animal model

Now, in new research posted to the bioRxiv preprint server, scientists at Novavax, Inc. present a vaccine including recombinant influenza hemagglutinin (HA) antigen along with recombinant SARS-CoV-2 spike protein, with saponin Matrix-M adjuvant. Both have passed independent safety tests in phase 1 trials.

10 May 2021

CD4 News and Research

SARS-CoV-2 variants partially escape humoral immunity, but not T cells responses, study finds

A novel multi-epitope COVID-19 vaccine developed using reverse vaccinology

Intensity and duration of SARS-CoV-2 immunity may depend on ABO blood group

Tissue-resident memory T cells found in lungs of people who had COVID-19 10 months ago

An exploratory study of T-cell and antibody responses after COVID-19 mRNA vaccination

Immunologists decode T cell responses that occur during COVID-19 infection

Human T cells can target more than 1,400 sites on SARS-CoV-2 virus

Next-generation SARS-CoV-2 subunit vaccine candidate elicits powerful immunity in preclinical trials

Facets of SARS-CoV-2 infection and animal models

Are COVID-19-related complications in children explained by abnormal immune responses?

COVID-19 mRNA vaccines safe and effective for pregnant and breastfeeding women

Moderna and Pfizer-BioNTech vaccines induce robust T cell response against SARS-CoV-2 variants

Unique pre-clinical model enables study of HIV infection and testing of new therapies

Pfizer-BioNTech COVID-19 vaccine effective in patients with myeloproliferative neoplasms

T cell populations in nasal mucosa expand after COVID-19 mRNA vaccination

Research suggests Pfizer-BioNTech COVID-19 vaccine reprograms innate immune responses

Combo COVID-flu vaccine protects against current and emerging variants in animal model

Aberrant immune features in healthy elderly and male subjects with severe COVID-19 may predate infection

Pan-COVID-19 vaccine protects mice against SARS-CoV-2 variants

Class I HLA alleles shape CD8+ T cell repertoire in SARS-CoV-2 infection

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News